DOP2013000299A - Anticuerpos anti-angptl3 y usos de los mismos - Google Patents
Anticuerpos anti-angptl3 y usos de los mismosInfo
- Publication number
- DOP2013000299A DOP2013000299A DO2013000299A DO2013000299A DOP2013000299A DO P2013000299 A DOP2013000299 A DO P2013000299A DO 2013000299 A DO2013000299 A DO 2013000299A DO 2013000299 A DO2013000299 A DO 2013000299A DO P2013000299 A DOP2013000299 A DO P2013000299A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- diseases
- hangptl3
- disorders
- human
- hypertriglyceridemia
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se proporciona un anticuerpo totalmente humano o fragmento de fijación de antígeno de un anticuerpo humano que se fija específicamente e inhibe o interfiere con al menos una actividad de la proteína 3 de tipo angiopoyetina humana (hANGPTL3). Los anticuerpos anti-hANGPTL3 humanos son útiles en el tratamiento de enfermedades o trastornos asociados con ANGPTL3, tales como hipertrigliceridemia, hiperlipoproteinemia y dislipidemia, con inclusión de hipertrigliceridemia, hipercolesterolemia, quilomicronemia, etcétera. Adicionalmente, los anticuerpos anti-hANGPTL3 pueden administrarse a un individuo en necesidad de ello para prevenir o tratar enfermedades o trastornos, para los cuales el metabolismo anormal de los lípidos es un factor de riesgo. Tales enfermedades o trastornos incluyen enfermedades cardiovasculares, tales como ateroesclerosis y enfermedades de las arterias coronarias; pancreatitis aguda; esteatohepatitis no alcohólica (NASH); diabetes; obesidad; y análogos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161498518P | 2011-06-17 | 2011-06-17 | |
| US201161578309P | 2011-12-21 | 2011-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2013000299A true DOP2013000299A (es) | 2014-04-15 |
Family
ID=46298728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2013000299A DOP2013000299A (es) | 2011-06-17 | 2013-12-11 | Anticuerpos anti-angptl3 y usos de los mismos |
Country Status (42)
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR087329A1 (es) | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| WO2017011929A1 (zh) * | 2015-07-17 | 2017-01-26 | 北京大学第一医院 | 检测血清血管生成素样蛋白2含量的物质在制备检测肝脏炎症和纤维化程度产品中的应用 |
| TW202340452A (zh) | 2015-08-04 | 2023-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
| TW201713690A (zh) | 2015-08-07 | 2017-04-16 | 再生元醫藥公司 | 抗ａｎｇｐｔｌ８抗體及其用途 |
| PT3416684T (pt) | 2016-02-17 | 2023-07-04 | Regeneron Pharma | Métodos para tratamento ou prevenção da aterosclerose por administração de um inibidor da angptl3 |
| MA43734A (fr) * | 2016-03-03 | 2018-11-28 | Regeneron Pharma | Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3 |
| WO2017177181A1 (en) * | 2016-04-08 | 2017-10-12 | Regeneron Pharmaceuticals, Inc. | Methods for treating hyperlipidemia with an angptl8 inhibitor and an angptl3 inhibitor |
| CA3021884A1 (en) * | 2016-04-28 | 2017-11-02 | Regeneron Pharmaceuticals, Inc. | Methods for treating patients with familial hypercholesterolemia |
| EP3504328A1 (en) | 2016-08-24 | 2019-07-03 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| CA3044249A1 (en) | 2016-11-17 | 2018-05-24 | Regeneron Pharmaceuticals, Inc. | Methods of treating obesity with anti-angptl8 antibodies |
| BR112020000127A2 (pt) | 2017-07-06 | 2020-07-07 | Regeneron Pharmaceuticals, Inc. | método para selecionar um hidrolisado de soja, e, glicoproteína |
| US11977081B2 (en) | 2017-12-18 | 2024-05-07 | Regeneron Pharmaceuticals, Inc. | ANGPTL8 assay and uses thereof |
| AU2018392334A1 (en) | 2017-12-22 | 2020-05-28 | Regeneron Pharmaceuticals, Inc. | System and method for characterizing drug product impurities |
| AU2019215363A1 (en) | 2018-01-31 | 2020-07-23 | Regeneron Pharmaceuticals, Inc. | System and method for characterizing size and charge variant drug product impurities |
| TW202311746A (zh) | 2018-02-02 | 2023-03-16 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| SG11202006310PA (en) | 2018-02-28 | 2020-07-29 | Regeneron Pharma | Systems and methods for identifying viral contaminants |
| CA3089655A1 (en) | 2018-03-19 | 2019-09-26 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| EP3774841A1 (en) | 2018-08-27 | 2021-02-17 | Regeneron Pharmaceuticals, Inc. | Use of raman spectroscopy in downstream purification |
| BR112020026348A2 (pt) | 2018-08-30 | 2021-03-30 | Regeneron Pharmaceuticals, Inc. | Método para avaliar a estequiometria e distribuição de tamanho de complexos de proteínas, para selecionar um medicamento de proteína principal e para caracterizar complexos de proteínas, e, composição farmacêutica |
| US20220025344A1 (en) * | 2018-11-26 | 2022-01-27 | Novartis Ag | Lpl-gpihbp1 fusion polypeptides |
| TWI747098B (zh) | 2018-12-21 | 2021-11-21 | 美商美國禮來大藥廠 | 抗angptl3/8複合物抗體及其使用方法 |
| US11674968B2 (en) | 2019-01-16 | 2023-06-13 | Regeneran Pharmaceuticals, Inc. | Methods for identifying free thiols in proteins |
| US20220144961A1 (en) * | 2019-03-11 | 2022-05-12 | Xyence Therapeutics, Inc. | Cd27-binding antibodies and uses thereof |
| JP2022532503A (ja) | 2019-05-13 | 2022-07-15 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 改善された競合的リガンド結合アッセイ |
| US20200369760A1 (en) | 2019-05-24 | 2020-11-26 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-angptl3 antibodies |
| CN112062845B (zh) * | 2019-06-10 | 2022-09-02 | 山东博安生物技术股份有限公司 | Angptl3结合片段及其用途 |
| US20220380425A1 (en) * | 2019-07-04 | 2022-12-01 | Cadila Healthcare Limited | Angptl3 based vaccine for the treatment of liver disease |
| CA3216345A1 (en) | 2019-09-24 | 2021-04-01 | Regeneron Pharmaceuticals, Inc. | Systems and methods for chromatography use and regeneration |
| IL293112A (en) | 2019-11-25 | 2022-07-01 | Regeneron Pharma | Sustained release formulations using non-aqueous emulsions |
| CN110938144B (zh) * | 2019-11-27 | 2022-07-26 | 复旦大学附属儿科医院 | 一种抗angptl3单克隆抗体及其在制备治疗肾病综合征药物中的用途 |
| JP7342279B2 (ja) | 2020-01-21 | 2023-09-11 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | グリコシル化タンパク質の電気泳動のための脱グリコシル化方法 |
| US20230138315A1 (en) * | 2020-01-22 | 2023-05-04 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-angptl3 antibody and use thereof |
| CN116209772A (zh) | 2020-08-31 | 2023-06-02 | 瑞泽恩制药公司 | 用于提高细胞培养性能和减少天冬酰胺序列变体的天冬酰胺补料策略 |
| IL303027A (en) | 2020-11-25 | 2023-07-01 | Regeneron Pharma | Sustained release formulations by creating a non-aqueous membrane emulsion |
| WO2022133135A1 (en) | 2020-12-17 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Fabrication of protein-encapsulating microgels |
| TW202233827A (zh) | 2021-01-20 | 2022-09-01 | 美商再生元醫藥公司 | 改良細胞培養中蛋白質效價的方法 |
| BR112023017442A2 (pt) | 2021-03-03 | 2023-09-26 | Regeneron Pharma | Métodos para identificar regiões em uma proteína e para modificar a viscosidade de uma droga proteica, e, droga proteica |
| WO2022187353A1 (en) * | 2021-03-05 | 2022-09-09 | Anji Pharmaceuticals Inc. | Methods and compositions for treating sepsis |
| KR20230162932A (ko) | 2021-03-26 | 2023-11-29 | 리제너론 파아마슈티컬스, 인크. | 혼합 프로토콜 개발을 위한 방법 및 시스템 |
| US20240092884A1 (en) * | 2021-03-30 | 2024-03-21 | Children's Hospital Of Fudan University | Anti-angptl3 antibody or antigen-binding fragment thereof, and preparation method and use thereof |
| EP4348234A1 (en) | 2021-06-01 | 2024-04-10 | Regeneron Pharmaceuticals, Inc. | Micropchip capillary electrophoresis assays and reagents |
| CN117545769A (zh) * | 2021-07-21 | 2024-02-09 | 江苏恒瑞医药股份有限公司 | 一种抗angptl3抗体或其抗原结合片段的药物组合物及其用途 |
| US20230077710A1 (en) | 2021-09-08 | 2023-03-16 | Regeneron Pharmaceuticals, Inc. | HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS |
| AU2022348521A1 (en) | 2021-09-20 | 2024-04-04 | Regeneron Pharmaceuticals, Inc. | Methods of controlling antibody heterogeneity |
| CA3230985A1 (en) | 2021-10-07 | 2023-04-13 | Ross BROWNE | Ph meter calibration and correction |
| TW202323817A (zh) | 2021-10-07 | 2023-06-16 | 美商再生元醫藥公司 | Ｐｈ建模及控制之系統及方法 |
| CA3236367A1 (en) | 2021-10-26 | 2023-05-04 | Michelle Lafond | Systems and methods for generating laboratory water and distributing laboratory water at different temperatures |
| CN116284377A (zh) * | 2021-12-21 | 2023-06-23 | 复旦大学 | 抗人血管生成素3纳米抗体及其应用 |
| US20230193271A1 (en) * | 2021-12-22 | 2023-06-22 | Regeneron Pharmaceuticals, Inc. | Treatment Of Kidney Diseases With Angiopoietin Like 3 (ANGPTL3) Inhibitors |
| TW202346856A (zh) | 2022-03-18 | 2023-12-01 | 美商里珍納龍藥品有限公司 | 分析多肽變體的方法及系統 |
| TWI833641B (zh) * | 2022-05-02 | 2024-02-21 | 丹麥商諾佛 儂迪克股份有限公司 | 適於高濃度組成物及皮下投藥之新穎抗ａｎｇｐｔｌ３抗體 |
| CN117603361A (zh) * | 2022-08-22 | 2024-02-27 | 复旦大学附属儿科医院 | 包含angptl3单抗的融合蛋白 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020035058A1 (en) | 1996-05-15 | 2002-03-21 | The University Of Sheffield | Isopentenyl pyrophosphate isomerase (IPI) and/or prenyl transferase inhibitors |
| US6030831A (en) | 1997-09-19 | 2000-02-29 | Genetech, Inc. | Tie ligand homologues |
| US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| ES2284646T3 (es) | 2001-02-22 | 2007-11-16 | Jagotec Ag | Combinaciones de estatina-fibrato con efectos secundarios en ayunas-alimentado reducidos. |
| CN1615440A (zh) | 2001-11-16 | 2005-05-11 | 杰南技术公司 | 含有血管生成素－样蛋白质3angptl3的组合物及其使用方法 |
| EP2322203A3 (en) | 2002-10-29 | 2011-07-27 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| JP2005080508A (ja) | 2003-09-04 | 2005-03-31 | Sankyo Co Ltd | 脂質代謝改善剤の試験方法 |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| AU2006223579A1 (en) | 2005-03-11 | 2006-09-21 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
| AU2006326417B2 (en) | 2005-12-16 | 2012-05-24 | Regeneron Pharmaceuticals, Inc. | Therapeutic methods for inhibiting tumor growth with Dll4 antagonists |
| ES2398076T3 (es) | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | Anticuerpos de alta afinidad contra el receptor de IL-6 humano |
| LT2769992T (lt) * | 2006-10-02 | 2021-04-12 | Regeneron Pharmaceuticals, Inc. | Didelio afiniškumo žmogaus antikūnai, atpažįstantys žmogaus il-4 receptorių |
| MX2009006082A (es) * | 2006-12-08 | 2009-08-18 | Lexicon Pharmaceuticals Inc | Anticuerpos monoclonales contra la proteina 3 similar a angiopoyetina (angptl3). |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| EP2216016A1 (en) | 2009-02-06 | 2010-08-11 | LEK Pharmaceuticals d.d. | Process for the preparation of a pharmaceutical composition comprising ezetimibe |
| CN101852805B (zh) | 2009-03-31 | 2015-04-01 | 浙江大学 | Angptl3作为卵巢癌的诊断标记物的用途 |
| CN105601728B (zh) | 2009-07-14 | 2020-01-10 | 斯克里普斯研究所 | 间充质干细胞分化 |
| CN111700901A (zh) | 2010-01-08 | 2020-09-25 | Ionis制药公司 | 血管生成素样3表达的调节 |
| AR087329A1 (es) * | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
| BR122019026068B8 (pt) * | 2011-06-21 | 2022-10-18 | Alnylam Pharmaceuticals | Ácido ribonucleico de fita dupla (dsrna) para inibir a expressão de angptl3 e seu uso, composição farmacêutica e método in vitro para inibir a expressão de angptl3 em uma célula |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| PT3087183T (pt) | 2013-12-24 | 2020-10-08 | Ionis Pharmaceuticals Inc | Modulação da expressão da proteína relacionada com angiopoietina 3 |
| BR122020024443B1 (pt) | 2014-05-01 | 2022-02-22 | Ionis Pharmaceuticals, Inc | Composto e composição farmacêutica para modulação da expressão de angptl3 |
| RU2735521C2 (ru) | 2014-07-16 | 2020-11-03 | Санофи Байотекнолоджи | Способы лечения пациентов с гетерозиготной семейной гиперхолестеринемией (hefh) |
| TW201713690A (zh) | 2015-08-07 | 2017-04-16 | 再生元醫藥公司 | 抗ａｎｇｐｔｌ８抗體及其用途 |
| PT3416684T (pt) | 2016-02-17 | 2023-07-04 | Regeneron Pharma | Métodos para tratamento ou prevenção da aterosclerose por administração de um inibidor da angptl3 |
| MA43734A (fr) | 2016-03-03 | 2018-11-28 | Regeneron Pharma | Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3 |
| WO2017177181A1 (en) | 2016-04-08 | 2017-10-12 | Regeneron Pharmaceuticals, Inc. | Methods for treating hyperlipidemia with an angptl8 inhibitor and an angptl3 inhibitor |
| CA3021884A1 (en) | 2016-04-28 | 2017-11-02 | Regeneron Pharmaceuticals, Inc. | Methods for treating patients with familial hypercholesterolemia |
-
2012
- 2012-06-13 AR ARP120102099A patent/AR087329A1/es active IP Right Grant
- 2012-06-13 JO JOP/2012/0155A patent/JO3412B1/ar active
- 2012-06-14 PE PE2013002804A patent/PE20141166A1/es active IP Right Grant
- 2012-06-14 LT LTEP12727767.1T patent/LT2721065T/lt unknown
- 2012-06-14 MY MYPI2013004223A patent/MY160516A/en unknown
- 2012-06-14 SG SG2013087432A patent/SG195165A1/en unknown
- 2012-06-14 US US13/517,662 patent/US9018356B2/en active Active
- 2012-06-14 PL PL12727767T patent/PL2721065T3/pl unknown
- 2012-06-14 JP JP2014515976A patent/JP6400471B2/ja active Active
- 2012-06-14 MX MX2013014345A patent/MX337644B/es active IP Right Grant
- 2012-06-14 RS RS20181508A patent/RS58310B1/sr unknown
- 2012-06-14 AU AU2012271663A patent/AU2012271663B2/en active Active
- 2012-06-14 ES ES12727767T patent/ES2699499T3/es active Active
- 2012-06-14 TR TR2018/16591T patent/TR201816591T4/tr unknown
- 2012-06-14 SI SI201231444T patent/SI2721065T1/sl unknown
- 2012-06-14 UA UAA201314628A patent/UA114891C2/uk unknown
- 2012-06-14 PT PT12727767T patent/PT2721065T/pt unknown
- 2012-06-14 EP EP12727767.1A patent/EP2721065B1/en active Active
- 2012-06-14 RU RU2013155906A patent/RU2620064C2/ru active
- 2012-06-14 DK DK12727767.1T patent/DK2721065T3/en active
- 2012-06-14 CA CA2838867A patent/CA2838867C/en active Active
- 2012-06-14 MX MX2015017575A patent/MX361859B/es unknown
- 2012-06-14 CN CN201280038908.0A patent/CN103732624B/zh active Active
- 2012-06-14 EP EP18185031.4A patent/EP3418301A1/en not_active Withdrawn
- 2012-06-14 KR KR1020147000902A patent/KR102031007B1/ko active IP Right Grant
- 2012-06-14 WO PCT/US2012/042338 patent/WO2012174178A1/en active Application Filing
- 2012-06-15 UY UY0001039340A patent/UY39340A/es not_active Application Discontinuation
- 2012-06-15 TW TW101121453A patent/TWI644922B/zh active
- 2012-06-15 TW TW107135714A patent/TW201920261A/zh unknown
- 2012-06-15 TW TW106123582A patent/TW201815822A/zh unknown
- 2012-06-15 UY UY0001034137A patent/UY34137A/es not_active Application Discontinuation
-
2013
- 2013-11-25 IL IL229612A patent/IL229612B/en active IP Right Grant
- 2013-11-26 CR CR20130621A patent/CR20130621A/es unknown
- 2013-11-26 ZA ZA2013/08879A patent/ZA201308879B/en unknown
- 2013-12-06 NI NI201300136A patent/NI201300136A/es unknown
- 2013-12-11 CL CL2013003552A patent/CL2013003552A1/es unknown
- 2013-12-11 DO DO2013000299A patent/DOP2013000299A/es unknown
- 2013-12-11 GT GT201300306A patent/GT201300306A/es unknown
- 2013-12-13 CO CO13292222A patent/CO6821892A2/es unknown
- 2013-12-16 EC ECSP13013085 patent/ECSP13013085A/es unknown
- 2013-12-17 MA MA36579A patent/MA35190B1/fr unknown
-
2015
- 2015-03-24 US US14/667,121 patent/US9951127B2/en active Active
-
2018
- 2018-04-20 US US15/958,996 patent/US10358487B2/en active Active
- 2018-05-16 IL IL259436A patent/IL259436A/en active IP Right Grant
- 2018-07-06 JP JP2018128768A patent/JP2018166516A/ja active Pending
- 2018-12-11 CY CY181101324T patent/CY1120996T1/el unknown
- 2018-12-12 HR HRP20182098TT patent/HRP20182098T1/hr unknown
-
2019
- 2019-06-07 US US16/435,032 patent/US20190315851A1/en not_active Abandoned
-
2021
- 2021-09-01 NL NL301122C patent/NL301122I2/nl unknown
- 2021-09-06 HU HUS2100034C patent/HUS2100034I1/hu unknown
- 2021-09-06 LT LTPA2021009C patent/LTC2721065I2/lt unknown
- 2021-09-09 FI FIC20210028C patent/FIC20210028I1/fi unknown
- 2021-09-15 NO NO2021037C patent/NO2021037I1/no unknown
-
2022
- 2022-01-27 US US17/586,662 patent/US20220153825A1/en not_active Abandoned
- 2022-09-08 US US17/930,704 patent/US20220403016A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP13013085A (es) | Anticuerpos anti-angptl3 y usos de los mismos | |
| AR079708A1 (es) | Anticuerpos humanos que se unen a la proteina 4 de tipo angiopoyetina humana | |
| PH12019500440A1 (en) | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
| EA201490004A1 (ru) | Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей | |
| ECSP19025350A (es) | Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi) | |
| EA201500064A1 (ru) | Активаторы ampk и их применение в терапевтических целях | |
| BR112015011403A2 (pt) | uso de akkermansia para o tratamento de distúrbios metabólicos | |
| ECSP15005280A (es) | Agentes de unión de proteína de r-espondina humana (rspo3) y usos de los mismos | |
| UY32989A (es) | Coposiciones terapéuticas concentradas de fosfolípidos | |
| LT2013015A (lt) | Farmacinės kompozicijos | |
| CL2011000814A1 (es) | Uso de auna mikacina liposomal que comprende un lipido y amikacina para preparar un medicamento util para el tratamiento de un desorden pulmonar en un paciente. | |
| BR112013001299A2 (pt) | composições farmacêuticas e respectivo uso e métodos de tratamento de diabetes e doenças correlatas em paciente humano | |
| CL2013003298A1 (es) | Uso de metotrexato porque sirve para preparar un medicamento, útil en el tratamiento de enfermedades que necesiten tratamiento con un producto terapéutico que produzca autoinmunidad, administrado en un sólo ciclo. | |
| BR112016003584A8 (pt) | composições farmaceuticas e uso das mesmas para regressão de placa acelerada | |
| BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
| AR093620A1 (es) | Anticuerpos bmp-6 | |
| BR112018000909A2 (pt) | imunoconjugados de il22 | |
| BR112015014621A2 (pt) | Anticorpos anti-h7cr | |
| BR112017001146A2 (pt) | terapia com anticorpo anti-vegfr2 para carcinoma hepatocelular | |
| BR112013032132A2 (pt) | "uso de peptidase da família calicreína, de agente que aumenta a sua expressão ou de células que apresentam expressão ou atividade de rheb reduzida para prevenção ou tratamento de diabetes e distúrbio metabólico e aumento da sensibilidade à insulina, bem como métodos para determinar se composto de teste é agente terapêutico provável no tratamento de diabetes" | |
| TN2013000490A1 (en) | Anti-angptl3 antibodies and uses thereof | |
| TH149802A (th) | โปรตีนจับเกาะแอนติเจน |